Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754808 | 0.87 | HTR2A (0.50) | XIAPHTR2ASLC6A4KCNH2AR | |
| SCHEMBL12239001 | 0.75 | XIAP (0.57) | XIAPHTR2ASLC6A4KCNH2AR | |
| SCHEMBL12239002 | 0.74 | PDE2A (0.47) | PDE2ASLC6A4CYP2D6ALDH1A1KMT2A | |
| SCHEMBL18331711 | 0.74 | AR (0.44) | XIAPHTR2ASLC6A4KCNH2AR | |
| SCHEMBL755873 | 0.74 | DPP4 (0.50) | HTR2ASLC6A4KCNH2ARCYP3A4 | |
| SCHEMBL25962922 | 0.74 | HTR2A (0.49) | HTR2ASLC6A4KCNH2ARCYP1A2 | |
| SCHEMBL23123470 | 0.73 | PDE2A (0.53) | PDE2AHTR2ASLC6A4CYP1A2CYP2D6 | |
| SCHEMBL30932944 | 0.73 | PDE2A (0.53) | PDE2AHTR2ASLC6A4CYP1A2CYP2D6 | |
| SCHEMBL29757910 | 0.73 | PDE2A (0.53) | PDE2AHTR2ASLC6A4CYP1A2CYP2D6 | |
| SCHEMBL23123468 | 0.73 | PDE2A (0.53) | PDE2AHTR2ASLC6A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2188254-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | XIAP 2951/4885PDE2A 1220/4885HTR2A 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.